香蕉91成人一区二区三区飘花,91精品人妻一区二区三区蜜桃,四川少妇BBw搡BBBB槡BBBB,国产成人91一区二区三区APP
3358288340
CN
CN EN
Human Erythropoietin Injection(CHOCell)
EPOSINO is the first batch of recombinant human erythropoietin approved for R&D in China and obtained the New Drug Certificate and NMPA's official approval number. It is complete in dosage forms and strengths and firstly administrated by pre-filled syringes for more convenient clinical drug selection. As an industry-leading product, it has been accessed into and sold in more than 30 countries, including Brazil, the Philippines and Indonesia.
Drug description

【Indications】

①Anemia caused by renal dysfunction, including dialysis and non-dialysis patients;

②Perioperative erythrocyte mobilization;

③Anemia caused by chemotherapy for non-myeloid malignancies. (To be added)


【R&D and Commercial Production of EPOSINO】

In 1991, technicians obtained the first batch of efficiently and stably expressed EPOengineered cell lines in China through genetic engineering technology, screening and various identifications;


In 1993, preclinical pilotscale production processes and preclinical animal trials were successfully completed in cooperation with relevant institutes, and various tests by the National Institute for the Control of Pharmaceutical and Biological Products were also passed;


In February 1994, the phase I clinical trial was approved by the Bureau of Drug Policy & Administration of Ministry of Health;


In January 1996, the phase II clinical trial was approved by the Bureau of Drug Policy & Administration of Ministry of Health;


In phase II clinical trial of EPOSINO, recombinant human erythropoietin originators (Epogen manufactured by Amgen in the USA, and Recormon manufactured by BoehrinMan in Germany) were used as reference substances in the pair therapy with EPOSINO. A total of 102 patients with anemia due to chronic renal failure were treated with EPOSINO. The efficacy was observed and compared: "The total effective rate of EPOSINO was 91.2%, and that of the original drug was 89.2%. The difference was not significant and the efficacy was equivalent" (data from the phase II clinical trial of EPOSINO).


In October 1996, the first new drug certificate issued by the Ministry of Health in China was obtained;


In October 1997, the first approval number for trial production in China was obtained;


In August 1998, the first approval number for formal production in China was obtained, and the new drug belonged to Class II biological products.


In 1999, the first prefilled syringe packaging was launch in China to facilitate clinical medication selection;


In 2006, clinical approval was obtained for the indication of perioperative erythrocyte mobilization;


In 2009, the albumin-free drug product was granted a patent for invention;


In 2011, the indication for perioperative erythrocyte mobilization was approved;


In 2013, supplementary approval was obtained for the albumin-free formulation;


In 2017, the clinical trial on the anemia indication of cancer chemotherapy was carried out;


In 2020, the marketing authorization application for the anemia indication of cancer chemotherapy was submitted;


Drug description
一级A片黄女人高潮网站 | 国产寡妇亲子伦一区二区三区四区 | 大又大又粗又硬又爽少妇毛片 | 免费无码人婬片AAAA公交车 | 人人看人人做人人做人人 | 亚洲精品字幕在线观看 | 又大又长又粗又硬又黄又爽无遮挡 | 人妻边打电话边被躁91 | 亚洲铁杆无码在线观看视频 | 国产精品久久久久永久免费看 | 脫衣舞一区二区三区‘ | 免费白丝jk爆 乳美女 | 国产一级一厂片内射视频播放蘑菇 | 亚洲一区二区久久哔哩哔哩 | 精品国产乱码一区二区三区免费 | 国产拳头交一区二区免费 | 日本啪啪毛片一区二区 | 四川少妇A片免费观看 | 国产69精品久久久久红桃 | 极品粉嫩小仙女小泬 | 国产精品久久久久永久免费观看 | BBw揉BBBB搡BBBB动漫 | 国产91欧美成人A片男男 | 中文无码精品一区二区三区 | 日本无码中文字幕乱偷在线 | 二区三区五码高清 | 啊啊啊肏屄白浆操死我 | 成人黄色视频免费观看 | 亚洲精品8848四虎成人 | 91精品久久久久久久99蜜桃 | 中文字幕精品久久久久人妻红杏Ⅰ | 一区二区三区四区国产 | 近親相姦五十路人妻 | 国产乱人乱偷精品视频网站 | 亚洲无码一区二区在线观看 | 女人a级久久毛片 | 中出受孕中文字幕在线 | 8x8ⅹ拨牐拨牐永免费 | 大乳奶一级婬片A片无码小说姜怡 | 国产激情综合五月久久 | 欧美一级婬片A片免费软件 国产成人+ 8x8+高潮 |